MedTrace Logo

Micronutrients and Child Health Study

NCT00623857 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 612

Last updated 2014-11-17

No results posted yet for this study

Summary

The purpose of this study is to determine to what extent supplementation with zinc and other micronutrients are efficacious in preventing malaria in young Tanzanian children.

Conditions

Interventions

DIETARY_SUPPLEMENT

Zinc

Daily oral supplementation with zinc, 10 mg, for an average of 60 weeks

DIETARY_SUPPLEMENT

Vitamins and minerals other than zinc

Daily supplementation with vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks

DIETARY_SUPPLEMENT

Vitamins plus zinc and other minerals

Daily oral supplementation with zinc, vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks

DIETARY_SUPPLEMENT

Placebo

Daily oral supplementation with placebo for vitamins and all minerals; for an average of 60 weeks

Sponsors & Collaborators

  • Kilimanjaro Christian Medical Centre, Tanzania

    collaborator OTHER

  • Wageningen University

    lead OTHER

Principal Investigators

  • Hans Verhoef, PhD · Wageningen University, Cell Biology and Immunology Group

  • Raimos M Olomi, MD MMed MPH · Kilimanjaro Christian Medical Centre

  • Huub FJ Savelkoul, PhD · Wageningen University, Cell Biology and Immunology Group

  • John F. Shao, MD · Kilimanjaro Christian Medical Centre

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
6 Months
Max Age
60 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • Tanzania

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00623857 on ClinicalTrials.gov